Bioavailability and Toxicokinetics of Citrate-coated Silver Nanoparticles in Rats
Bioavailability and Toxicokinetics of Citrate-coated Silver Nanoparticles in Rats
复制标题
DOI：
10.1007/s12272-011-0118-z
复制
发表时间：
2011-01-01
影响因子：
6.7
通讯作者：
Lee, Byung Chun
中科院分区：
文献类型：
--
作者：
Park, Kwangsik;Park, Eun-Jung;Lee, Byung Chun
研究了柠檬酸盐包被的银纳米颗粒（AgNPs;尺寸，TEM直径为7.9 +/- 0.95 nm）的生物利用度、组织分布、血液浓度和排泄。雄性SD大鼠通过单次口服或静脉内施用1或10 mg/kg AgNP进行治疗。分别于给药后10 min、1、2、4、8、24、48、96 h测定血银浓度。还在给药后24和96 h测量了肝脏、肺和肾脏中的银。在治疗后24 h测定银纳米颗粒通过粪便和尿液的排泄。口服给药后，大多数AgNPs被发现在粪便中，其血液浓度很低。这表明通过胃肠道的吸收不好。然而，在尾静脉注射后，在血液中检测到高水平的银。当大鼠注射1 mg/kg AgNPs时，血液中的银浓度在注射后10 min显著升高，随后该水平降低。在用10 mg/kg AgNPs处理的大鼠中，升高的水平没有降低，而是在实验期间维持。基于AUC（口服）/AUC（iv）的值，口服施用的AgNP的生物利用度在用1 mg/kg AgNP处理的组中为1.2%，在用10 mg/kg AgNP处理的组中为4.2%。银纳米颗粒在肝脏、肺和肾脏中积累;积累的银纳米颗粒被释放到血流中。与粪便中的水平相比，尿液中的AgNP水平极低。当给大鼠注射AgNPs时，在治疗后24 h在粪便中也检测到这些颗粒，这表明AgNPs的胆汁分泌。
Bioavailability, tissue distribution, blood concentration, and excretion of citrate-coated silver nanoparticles (AgNPs; size, 7.9 +/- 0.95 nm by TEM diameter) were investigated. Male SD rats were treated by a single oral or intravenous administration of either 1 or 10 mg/kg AgNPs. Silver concentration of blood was determined at 10 min, and at 1, 2, 4, 8, 24, 48, and 96 h after treatment. Silver in the liver, lungs, and kidneys was also measured at 24 and 96 h after treatment. Excretion of silver nanoparticles via feces and urine was determined at 24 h after treatment. After oral administration, most AgNPs were found in feces, and their blood concentration was very low. This suggests that absorption through the gastrointestinal tract was not good. However, a high level of silver in the blood was detected after tail vein injection. When rats were injected with 1 mg/kg AgNPs, the silver concentration of blood was significantly elevated at 10 mm after injection; the level subsequently decreased. In the rats treated with 10 mg/kg AgNPs, the elevated level did not decrease, but was maintained during the experimental period. On the basis of the values of AUC(oral)/AUC(iv), the bioavailability of orally administered AgNPs was 1.2% in the group treated with 1 mg/kg AgNPs and 4.2% in the group treated with 10 mg/kg AgNPs. AgNPs accumulated in the liver, lungs, and kidneys; the accumulated AgNPs were released into the blood stream. AgNP levels in the urine were extremely low compared to the levels in the feces. When rats were injected with AgNPs, these particles were also detected in feces at 24 h after treatment, which suggests bile secretion of AgNPs.